| Bibliografia |
| |
| 1. Jacobson IM et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005;100:2453-2462 |
| |
| 2. Jensen DM et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon alfa-2b. Ann InternMed 2009;150(8):528-40 |
| |
| 3. Kaiser S et al. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40Kd) plus ribavirin for 72 weeks. Hepatology 2008;48(4)1140A |
| |
| 4. Lee WM et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472-492 |
| |
| 5. Lindsay KL et al. Blunted cytopenias andweight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastro Hep. 2008:6:234-241 |
| |
| 6. Poynard T et al. Platelet count predicts sustained viral response (SVR) in the treatment of previous interferon /ribavirin non-responders (NR): results from the EPIC3 program. Programand abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008;Milan, Italy. Abstract 822 |
| |
| 7. Poynard T et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) non responders (NR); final results from the EPIC3 program. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008;Milan, Italy. Abstract 988 |
| |
| 8. Sherman M et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006;55:1631-1638 |
| |
| 9. Shiffman ML et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023 |
| |
| 10. Shiffman ML et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103-112 |
